Emil D. Kakkis, President & CEO at Ultragenyx Pharmaceutical Inc. (RARE), sold 171,868 shares at $42.48 ($7.2M) on 2025-02-28, disclosed to the SEC on 2025-03-04.
Scheduled sale ($7.2M) by President & CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $42.48 | 25,000 | $1.1M | 14.7% |
| 2 | $42.10 | 73,434 | $3.1M | 42.7% |
| 3 | $42.10 | 73,434 | $3.1M | 42.7% |
| Total | $42.16 avg | 171,868 | $7.2M | 100% |
| Filing → |
| RARE | SELL | 2024-12-11 | $414K | — | Filing → |
| RARE | SELL | 2024-09-05 | $1.1M | — | Filing → |
| RARE | SELL | 2024-08-07 | $1.0M | — | Filing → |